Innovent Biologics
1801
Performance
About Innovent Biologics
Innovent Biologics is a biopharmaceutical company focused on the development and commercialization of innovative therapies, primarily in oncology and autoimmune diseases. Headquartered in China, it develops monoclonal antibodies and other biologics, with a broad product pipeline and collaboration strategy to advance cancer and immune-mediated disease treatments across Asia and globally. The company emphasizes integrated discovery, development, manufacturing, and partner programs to bring therapies to market. Its Chinese language site highlights research areas, product lines, and corporate governance, indicating an emphasis on global collaboration and patient-centric innovation.
Recent News
Pfizer Inks $10 Billion Oncology Pact with China’s Innovent Biologics
The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration
STAT+: Pharmalittle: We’re Reading About Replimune Drug Getting Third Try at FDA Approval, a Pfizer Deal in China, and More
The Company that Built TikTok’s Algorithm Is Now Designing Drugs for Diseases Pharma Called Undruggable
Pfizer Signs Potential $10.5bn Oncology Licencing Deal with China’s Innovent
China Investors Energise Hong Kong Biotech Stocks. Is Foreign Money Missing Out?
Pfizer Inks up to $10.5 Billion Deal with China’s Innovent Biologics
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
ByteDance’s Anew Labs Unveils First AI‑Designed Small‑Molecule Immunotherapy
Lilly Returns to Innovent to Partner on Cancer and Immune Diseases
Hutchmed, Innovent Win Chinese Approval for Fruquintinib‑Sintilimab Combo in Kidney Cancer
Innovent Shares Jump on First Profit, Obesity Drug Momentum
Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration
The Peptide Economy vs the Healthcare AI Economy: Which Side of the Trade Matters More
Roche Spends $570M on Another ADC Agreement With China’s MediLink
Pfizer Inks $10.5 B Oncology Partnership with China's Innovent Biologics
Pfizer’s TALZENNA‑XTANDI Combo Cuts Progression Risk 52% in HRR‑Mutated Prostate Cancer
Recent Deals
No recent deals for this company.